10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2015 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 11, 2016) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash flows from operating activities: | |||
| Net income | $ 636,056 | 338,126 | 413,738 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 74,909 | 52,686 | 41,204 |
| Non-cash compensation expense | 459,049 | 321,750 | 215,377 |
| Loss on Extinguishment of Debt | 18,861 | 33,469 | 0 |
| Other non-cash charges and expenses, net | 33,701 | 44,102 | 46,751 |
| Increase (Decrease) in Deferred Income Taxes | (121,623) | (53,276) | 62,195 |
| Changes in assets and liabilites | |||
| Increase in Sanofi, Bayer HealthCare, and trade accounts receivable | (491,421) | (34,927) | (245,472) |
| Increase in Inventories | (111,825) | (56,947) | (47,956) |
| (Increase) decrease in prepaid expenses and other assets | (79,476) | (45,327) | 7,571 |
| Increase (decrease) in deferred revenue | 608,892 | (8,403) | (41,496) |
| Increase in accounts payable, accrued expenses and other liabilities | 303,657 | 161,182 | 136,684 |
| Total adjustments | 694,724 | 414,309 | 174,858 |
| Net cash provided by operating activities | 1,330,780 | 752,435 | 588,596 |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (557,105) | (564,188) | (577,278) |
| Sales or maturities of marketable securities | 327,437 | 476,417 | 378,146 |
| Capital expenditures | (677,933) | (333,006) | (156,323) |
| Net cash used in by investing activities | (907,601) | (420,777) | (355,455) |
| Cash flows from financing activities: | |||
| Proceeds from (Repayments of) Long-term Debt and Capital Securities | 26,020 | (1,095) | (2,024) |
| Repayments of convertible senior debt | (166,467) | (220,639) | 0 |
| Payments in connection with reduction of outstanding warrants | (573,487) | (294,552) | 0 |
| Proceeds from issuance of Common Stock | 206,358 | 126,045 | 57,393 |
| Payments in connection with Common Stock tendered for employee tax obligations | (160,537) | (267,584) | (195,087) |
| Excess tax benefit from stock-based compensation | 405,317 | 439,278 | 211,909 |
| Net cash (used in) provided by financing activities | (262,796) | (218,547) | 72,191 |
| Net increase in cash and cash equivalents | 160,383 | 113,111 | 305,332 |
| Cash and cash equivalents at beginning of period | 648,719 | 535,608 | |
| Cash and cash equivalents at end of period | 809,102 | 648,719 | 535,608 |
| Cash paid for interest (net of amounts capitalized) | 10,582 | 20,348 | 23,197 |
| Cash paid for income taxes | 276,092 | 59,847 | 1,057 |
| Class of Warrant or Right | |||
| Warrant | |||
| Payments in connection with reduction of outstanding warrants | (399,500) | (294,600) | |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |